27 February 2022 : Clinical Research
Serum Uric Acid Levels in Relation to Atrial Fibrillation: A Case-Control Study
Xia Zhong1ABCDEF*, Huachen Jiao2ABCFG, Dongsheng Zhao1BD, Jing Teng1CFDOI: 10.12659/MSM.934007
Med Sci Monit 2022; 28:e934007
Table 1 Demographic and clinical characteristics of control and atrial fibrillation group.
| Variable | Control group (n=492) | AF group (n=478) | P value |
|---|---|---|---|
| SUA, mg/dL | 5.35±1.55 | 5.66±1.90 | 0.006 |
| Male, mg/dL | 6.05±1.56 | 6.15±1.99 | 0.385 |
| Female, mg/dL | 4.58±1.21 | 5.33±1.88 | <0.001 |
| Hyperuricemia | 102 (20.7) | 142 (20.7) | 0.001 |
| Male, n (%) | 66 (64.7) | 70 (49.3) | 0.017 |
| Female, n (%) | 36 (35.3) | 72 (50.7) | |
| Age, years | 64.69±15.72 | 64.87±10.75 | 0.835 |
| Male, n (%) | 266 (54.1) | 253 (52.9) | 0.723 |
| Hypertension, n (%) | 172 (35.0) | 315 (65.9) | <0.001 |
| Diabetes, n (%) | 82 (16.7) | 135 (28.2) | <0.001 |
| CHD, n (%) | 146 (29.7) | 443 (72.7) | <0.001 |
| Scr, μmoI/L | 66.95±34.43 | 78.23±55.15 | <0.001 |
| FBG, mmol/L | 5.97±1.80 | 6.10±1.97 | 0.284 |
| ALT, U/L | 17 (12–25) | 16 (12–24) | 0.424 |
| AST, U/L | 18 (15–23) | 19.5 (16–25) | 0.001 |
| ALT/AST | 1.15±0.51 | 1.28±0.55 | <0.001 |
| APOA1, g/L | 1.22±0.25 | 1.08±0.25 | <0.001 |
| APOB, g/L | 1.00±0.25 | 0.81±0.48 | <0.001 |
| ALB, g/L | 40.30±4.04 | 37.75±4.59 | <0.001 |
| Ig, g/L | 28.10±3.99 | 28.48±4.35 | 0.156 |
| A/G | 1.46±0.22 | 1.35±0.24 | <0.001 |
| PAB, mg/L | 227.69±52.68 | 190.63±60.78 | <0.001 |
| Lp (a), mg/L | 14 (6.3–27.9) | 14.5 (7.85–28.78) | 0.160 |
| β-blockers, n (%) | 109 (22.2) | 367 (76.8) | <0.001 |
| CCBs, n (%) | 102 (20.7) | 162 (33.9) | <0.001 |
| ACEI/ARB, n (%) | 104 (21.1) | 284 (59.4) | <0.001 |
| Statins, n (%) | 128 (26.0) | 308 (64.4) | <0.001 |
| Data are presented as mean±standard deviation (SD), median (interquartile range [IQR]), or n (%). AF – atrial fibrillation; CHD – coronary heart disease; Scr – serum creatinine; FBG – fasting blood glucose; ALT – alanine aminotransferase; AST – aspartate aminotransferase; AST/ALT – aspartate aminotransferase/alanine aminotransferase; APOA1 – serum apolipoprotein A1; APOB – serum apolipoprotein B; ALB – albumin; Ig – immunoglobulin; A/G – albumin/globulin; PAB – prealbumin; Lp (a) – lipoprotein (a); CCBs – calcium channel blockers; ACEI/ARB – angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. | |||